论文部分内容阅读
上海市第十三制药厂试制的门冬氨酸钾镁于1983年4月经上海市卫生局批准投入生产,当时用于心功能不全的治疗,但上海瑞金医院等单位试用本品治疗病毒性肝炎高胆红素血症,获得可喜的苗子,后由11所医院组成扩大临床协作组,用双盲法对225例急性黄疸型肝炎(血清胆红素均在4mg/dl以上)进行了疗效研究,发现治疗组111例中有效110例,占99.1％;安慰剂组114例,有效107例,占92.9％(p<0.05)。 1984年3月15日,上海市卫生局召开门冬氨酸钾镁鉴定会。会议认为,本品治疗急性黄疸型肝炎高胆红素血症有效,对重度黄疸病例的退黄作用也较好,对肝昏迷有清醒作用,为治疗病毒性肝炎提供了新的有效药物。
Shanghai thirteenth pharmaceutical trial trial of potassium aspartate magnesium in April 1983 by the Shanghai Municipal Health Bureau approved the production, was used for the treatment of cardiac insufficiency, but the Shanghai Ruijin Hospital and other units try this product for the treatment of viral hepatitis Hyperbilirubinemia, to obtain gratifying seedlings, followed by 11 hospitals to expand the clinical cooperation group, double-blind method of 225 cases of acute jaundice hepatitis (serum bilirubin in 4mg / dl above) were studied In the 111 cases of treatment group, 110 cases were found to be effective, accounting for 99.1%. In the placebo group, 114 cases were effective, 107 cases were effective, accounting for 92.9% (p <0.05). March 15, 1984, Shanghai Municipal Health Bureau held a potassium magnesium aspartate appraisal meeting. The meeting believes that this product is effective in treating acute jaundice hepatitis hyperbilirubinaemia, and has a good effect on removing jaundice in cases of severe jaundice and a clear effect on hepatic coma, thus providing a new and effective drug for the treatment of viral hepatitis.